Novartis International AG http://www.novartis.com Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges 2012-04-24T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1605231.shtml FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers 2012-02-13T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1584870.shtml Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease 2012-02-07T22:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1583402.shtml Novartis extends commitment to help achieve final elimination of leprosy 2012-01-30T12:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1581023.shtml Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579903.shtml Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis International BioCamp spotlights how diversity spurs innovation across the company and inspires future science leaders 2011-08-29T07:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1541763.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers for 2011-2012 influenza season 2011-07-15T22:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531411.shtml Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1523978.shtml Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA 2011-06-16T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1523779.shtml Novartis candidate vaccine Bexsero® shows significant potential in providing broad coverage against meningococcal serogroup B infections 2011-06-09T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1522283.shtml Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly 2011-05-19T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1517375.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China 2011-03-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1498805.shtml Novartis appoints Naomi Kelman as new Head of the Novartis OTC division 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1489895.shtml FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for use in children from 2 years of age 2011-01-31T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1483545.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Novartis submits Bexsero®, a multi-component meningococcal B vaccine, for regulatory review in Europe 2010-12-23T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1475256.shtml Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 2010-11-17T11:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1463217.shtml New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains 2010-11-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1458801.shtml Phase III data show that Novartis meningococcal vaccine Menveo® demonstrated robust immunogenicity in infants 2010-10-25T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1454719.shtml Novartis Phase III study indicates MF59® adjuvanted influenza vaccine, Fluad®, is 75 percent more efficacious than studied non-adjuvanted vaccines in young children 2010-10-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1454259.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis announces agreement to develop influenza vaccines using revolutionary "synthetic genomics" technology 2010-10-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1449685.shtml Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza 2010-09-24T17:38:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446813.shtml Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease 2010-09-12T17:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1443940.shtml Novartis International BioCamp provides forum for future research and business leaders to engage in scientific innovation 2010-08-30T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1441156.shtml Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio 2010-08-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1440394.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Starke Performance der Divisionen Pharmaceuticals und Alcon im ersten Quartal; die Gesamtergebnisse des Konzerns wurden durch erwartete Herausforderungen beeinträchtigt 2012-04-24T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1605233.shtml Novartis verlängert Engagement für eine Welt ohne Lepra 2012-01-30T12:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1581025.shtml Novartis erzielt 2011 eine starke zugrundeliegende finanzielle Performance und erwartet für 2012 einen Umsatz auf dem Niveau des Jahres 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1579905.shtml Novartis erzielt im dritten Quartal eine starke finanzielle Performance sowie Fortschritte in der Pipeline 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1557502.shtml Novartis International BioCamp unterstreicht Bedeutung von Diversität für Innovation im Unternehmen und inspiriert künftige wissenschaftliche Führungskräfte 2011-08-29T07:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1541774.shtml Novartis erzielt im zweiten Quartal 2011 starke Finanzergebnisse und erreicht vier wichtige Zulassungen 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1531821.shtml Novartis beginnt mit dem Bau einer neuen, hochmodernen pharmazeutischen Produktionsanlage in St. Petersburg, Russland 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1523980.shtml Novartis startet kraftvoll in das Jahr 2011 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1507512.shtml Novartis ernennt Naomi Kelman zur neuen Leiterin der OTC-Division von Novartis 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1489896.shtml Innovation als treibende Kraft: Novartis erzielt 2010 ein zweistelliges Wachstum 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1482784.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Internationales BioCamp von Novartis bietet künftigen Spitzenkräften in Forschung und Wirtschaft Einblicke in wissenschaftliche Innovation 2010-08-30T11:20:04+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1441226.shtml Novartis übernimmt die 77%ige Mehrheitsbeteiligung an Alcon und ergänzt ihr führendes Gesundheitsportfolio durch eine neue Wachstumsplattform im Bereich der Augenheilkunde 2010-08-26T11:35:03+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1440553.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Le BioCamp de Novartis International illustre combien la diversité favorise l'innovation au sein de l'entreprise et inspire les futurs leaders de la science. 2011-08-29T07:30:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1541775.shtml